Intravenous Immunoglobulin Market Overview:

The global intravenous immunoglobulin market was valued at $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and nontherapeutic applications. Different classes of immunoglobulin such as IgG, IgA, and IgM are used for the treatment of various immunological and neurological diseases.

Get more information on this report: Request Sample Pages

The major factors driving the growth of the intravenous immunoglobulin market includes significant rise in geriatric population & number of hemophilic patients, improved technologies pertaining to the immunoglobulin production, and enhanced purification techniques (with better plasma yield). Furthermore, surge in prevalence diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, and others is expected to boost the market growth. However, stringent government regulations toward the use of intravenous immunoglobulin products and high risk of side effects associated with them are expected to hamper the growth of the market. On the contrary, high adoption of intravenous immunoglobulins for the treatment of various diseases is expected to create lucrative opportunities in the near future.

Get more information on this report: Request Sample Pages

Application segment review

Based on application, the global intravenous immunoglobulin market is divided into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. The hypogammaglobulinemia segment was the highest contributor to the market in 2017, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the significant rise in the prevalence of hypogammaglobulinemia disorder across the globe over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is ~2 per 100,000 population yearly, globally.

Get more information on this report: Request Sample Pages

Region segment review

Based on region, the intravenous immunoglobulin market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the largest contributor toward the global market, followed by Asia-Pacific. These regions collectively occupy almost 75% of the global market revenue. Presence of the largest plasma production facilities and high adoption rate in the developed countries majorly boost the market growth. However, LAMEA is projected to register the highest growth rate during the forecast period.

The report provides extensive competitive analysis and profiles of key market players that includes Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer Healthcare.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

Get more information on this report: Request Sample Pages

Key Benefits for Intravenous Immunoglobulin Market:

• The study provides an in-depth analysis of the global intravenous immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided.
• A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
• An extensive analysis of the key segments of the industry helps to understand the trends in the global allergy treatment market.
• Key players and their strategies are provided to understand the competitive outlook of the industry.

 Key Market Segments

• By APPLICATION
  • Hypogammaglobulinemia
  • Chronic Inflammatory demyelinating polyneuropathy (CIDP)
  • Primary immunodeficiency diseases
  • Myasthenia Gravis
  • Multifocal motor neuropathy
  • Idiopathic thrombocytopenic purpura (ITP)
  • Inflammatory myopathies
  • Specific antibody deficiency
  • Guillain-Barre syndrome
  • Others
• By PRODUCT
  • IGG
  • IGA
  • IGM
  • IGE
  • IGD
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Austria
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Saudi Arabia
    • Argentina
    • Brazil
    • Turkey
    • Rest of LAMEA

 
Key Market Players

• CSL LIMITED
• BAXTER INTERNATIONAL INC.
• LFB SA (LFB BIOTECHNOLOGIES SAS)
• BAYER AG
• CHINA BIOLOGIC PRODUCTS, INC.
• TAKEDA PHARMACEUTICAL COMPANY LIMITED
• BIOTEST AG
• OCTAPHARMA AG
• KEDRION BIOPHARMA INC.
• GRIFOLS S.A.

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools & models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Overview of Immunoglobulin

3.2.1.    Patented products
3.2.2.    Epidemiology and economic burden of chronic conditions

3.3.    Key findings

3.3.1.    Top Investment Pockets

3.4.    Porter’s five forces analysis
3.5.    Value chain analysis

3.5.1.    Primary activities
3.5.2.    Support activities

3.6.    Market share analysis, 2017
3.7.    Product scenario in intravenous immunoglobulin market
3.8.    Government regulations and reimbursements

3.8.1.    U.S.
3.8.2.    Europe
3.8.3.    France
3.8.4.    Germany
3.8.5.    Italy
3.8.6.    China
3.8.7.    Japan
3.8.8.    India

3.9.    Indications for immunoglobulin

3.9.1.    U.S. FDA indications
3.9.2.    EMA

3.10.    Component analysis of immunoglobulin G (IgG)

3.10.1.    IgG1
3.10.2.    IgG2
3.10.3.    IgG3
3.10.4.    IgG4

3.11.    Market dynamics

3.11.1.    Drivers

3.11.1.1.    Rise in prevalence of immunodeficiency diseases
3.11.1.2.    Increase in adoption of immunoglobulin treatment
3.11.1.3.    Growth in incidence of bleeding disorders

3.11.2.    Restraints

3.11.2.1.    Stringent government regulations
3.11.2.2.    High cost of therapy

3.11.3.    Opportunities

3.11.3.1.    Opportunities in emerging economies
3.11.3.2.    Development of cost-effective therapeutics through large-scale production

CHAPTER 4:    IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Hypogammaglobulinemia

4.2.1.    Market size and forecast

4.3.    Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.3.1.    Market size and forecast

4.4.    Primary immunodeficiency diseases

4.4.1.    Market size and forecast

4.5.    Myasthenia Gravis

4.5.1.    Market size and forecast

4.6.    Multifocal motor neuropathy

4.6.1.    Market size and forecast

4.7.    Idiopathic thrombocytopenic purpura (ITP)

4.7.1.    Market size and forecast

4.8.    Inflammatory myopathies

4.8.1.    Market size and forecast

4.9.    Specific antibody deficiency

4.9.1.    Market size and forecast

4.10.    Guillain-Barre syndrome

4.10.1.    Market size and forecast

4.11.    Others

4.11.1.    Market size and forecast

CHAPTER 5:    IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1.    Overview

5.1.1.    IGG

5.1.1.1.    Key market trends

5.1.2.    Clinical interpretations
5.1.3.    IGA

5.1.3.1.    Key Market Trends

5.1.4.    Clinical interpretation
5.1.5.    IGM

5.1.5.1.    Key Market Trends

5.1.6.    Clinical interpretation
5.1.7.    IGE

5.1.7.1.    Key Market Trend

5.1.8.    Clinical interpretation
5.1.9.    IGD

5.1.9.1.    Key Market Trends

5.1.10.    Clinical interpretation

CHAPTER 6:    INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    North America

6.2.1.    Key trends and opportunities
6.2.2.    North America market size & forecast, by application
6.2.3.    North America market size & forecast, by country

6.2.3.1.    U.S. market size & forecast
6.2.3.2.    Canada market size & forecast
6.2.3.3.    Mexico market size & forecast

6.3.    Europe

6.3.1.    Key trends and opportunities
6.3.2.    Europe market size & forecast, by application
6.3.3.    Europe market size & forecast for immunoglobulin market, by country

6.3.3.1.    Germany market size & forecast
6.3.3.2.    France market size & forecast
6.3.3.3.    UK market size & forecast
6.3.3.4.    Italy market size & forecast
6.3.3.5.    Austria market size & forecast
6.3.3.6.    Russia market size & forecast
6.3.3.7.    Rest of Europe market size & forecast

6.4.    Asia-Pacific

6.4.1.    Key trends and opportunities
6.4.2.    Asia-Pacific market size & forecast, by application
6.4.3.    Asia-Pacific market size & forecast, by country

6.4.3.1.    Australia market size & forecast
6.4.3.2.    China market size & forecast
6.4.3.3.    India market size & forecast
6.4.3.4.    Japan market size & forecast
6.4.3.5.    Rest of Asia-Pacific market size & forecast

6.5.    LAMEA

6.5.1.    Key trends and opportunities
6.5.2.    LAMEA market size & forecast, by application
6.5.3.    LAMEA market size & forecast, by country

6.5.3.1.    Brazil market size & forecast
6.5.3.2.    Saudi Arabia market size & forecast
6.5.3.3.    Argentina market size & forecast
6.5.3.4.    Turkey market size & forecast
6.5.3.5.    Rest of LAMEA market size & forecast

CHAPTER 7:    COMPANY PROFILES

7.1.    BAXTER INTERNATIONAL INC.

7.1.1.    Company overview
7.1.2.    Company snapshot
7.1.3.    Operating business segments
7.1.4.    Product portfolio
7.1.5.    Business performance
7.1.6.    Key strategic moves and developments

7.2.    BAYER AG

7.2.1.    Company overview
7.2.2.    Company snapshot
7.2.3.    Operating business segments
7.2.4.    Product portfolio
7.2.5.    Business performance
7.2.6.    Key strategic moves and developments

7.3.    BIOTEST AG

7.3.1.    Company overview
7.3.2.    Company snapshot
7.3.3.    Operating business segments
7.3.4.    Product portfolio
7.3.5.    Business performance

7.4.    CHINA BIOLOGIC PRODUCTS, INC.

7.4.1.    Company overview
7.4.2.    Company snapshot
7.4.3.    Operating business segments
7.4.4.    Product portfolio
7.4.5.    Business performance

7.5.    CSL LIMITED

7.5.1.    Company overview
7.5.2.    Company snapshot
7.5.3.    Operating business segments
7.5.4.    Product portfolio
7.5.5.    Business performance

7.6.    GRIFOLS S.A.

7.6.1.    Company overview
7.6.2.    Company snapshot
7.6.3.    Operating business segments
7.6.4.    Product portfolio
7.6.5.    Business performance
7.6.6.    Key strategic moves and developments

7.7.    KEDRION BIOPHARMA INC.

7.7.1.    Company overview
7.7.2.    Company snapshot
7.7.3.    Operating business segments
7.7.4.    Product portfolio
7.7.5.    Business performance
7.7.6.    Key strategic moves and developments

7.8.    LFB SA (LFB BIOTECHNOLOGIES SAS)

7.8.1.    Company overview
7.8.2.    Company snapshot
7.8.3.    Operating business segments
7.8.4.    Product portfolio
7.8.5.    Business performance

7.9.    OCTAPHARMA AG

7.9.1.    Company overview
7.9.2.    Company snapshot
7.9.3.    Operating business segments
7.9.4.    Product portfolio
7.9.5.    Business performance

7.10.    TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1.    Company overview
7.10.2.    Company snapshot
7.10.3.    Operating business segments
7.10.4.    Product portfolio
7.10.5.    Business performance
7.10.6.    Key strategic moves and developments

LIST OF TABLES

TABLE 01.    COMMERCIALIZED IMMUNOGLOBULIN PRODUCTS
TABLE 02.    U.S. FDA INDICATIONS FOR IMMUNOGLOBULIN
TABLE 03.    EMA-APPROVED INDICATIONS FOR IMMUNOGLOBULIN
TABLE 04.    IGG SUBCLASS
TABLE 05.    FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 06.    DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY
TABLE 07.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 08.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAM)
TABLE 09.    COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 10.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 2017–2025 ($MILLION)
TABLE 11.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 12.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR CIDP, BY REGION, 2017–2025 ($MILLION)
TABLE 13.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 14.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION,  2017–2025 ($MILLION)
TABLE 15.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION,  2017–2025 (KILOGRAMS)
TABLE 16.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 2017–2025 ($MILLION)
TABLE 17.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 2017–2025 (KILOGRAMS)
TABLE 18.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION,  2017–2025 ($MILLION)
TABLE 19.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION,  2017–2025 (KILOGRAMS)
TABLE 20.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),  BY REGION, 2017–2025 ($MILLION)
TABLE 21.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 2017–2025 (KILOGRAMS)
TABLE 22.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 2017–2025 ($MILLION)
TABLE 23.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION,  2017–2025 (KILOGRAMS)
TABLE 24.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION,  2017–2025 ($MILLION)
TABLE 25.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION,  2017–2025 (KILOGRAMS)
TABLE 26.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME, BY REGION, 2017–2025 ($MILLION)
TABLE 27.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME), BY REGION,  2017–2025 (KILOGRAMS)
TABLE 28.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 2017–2025 ($MILLION)
TABLE 29.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 30.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 31.    GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, 2017-2025 (KILOGRAMS))
TABLE 32.    NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 33.    NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAMS)
TABLE 34.    NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 35.    NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 (KILOGRAMS)
TABLE 36.    EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 37.    EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAMS)
TABLE 38.    EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 39.    EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 (KILOGRAMS)
TABLE 40.    ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 41.    ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAMS)
TABLE 42.    ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
TABLE 43.    ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 (KILOGRAMS)
TABLE 44.    LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 45.    LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAMS)
TABLE 46.    LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 47.    LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 (KILOGRAMS)
TABLE 48.    BAXTER: COMPANY SNAPSHOT
TABLE 49.    BAXTER: OPERATING SEGMENTS
TABLE 50.    BAXTER: PRODUCT PORTFOLIO
TABLE 51.    BAYER: COMPANY SNAPSHOT
TABLE 52.    BAYER: OPERATING SEGMENTS
TABLE 53.    BAXTER: PRODUCT PORTFOLIO
TABLE 54.    BIOTEST: COMPANY SNAPSHOT
TABLE 55.    BIOTEST: OPERATING SEGMENTS
TABLE 56.    BIOTEST: OPERATING SEGMENT
TABLE 57.    CHINA BIOLOGIC COMPANY SNAPSHOT
TABLE 58.    CHINA BIOLOGIC PRODUCT PORTFOLIO
TABLE 59.    CSL: COMPANY SNAPSHOT
TABLE 60.    CSL: PRODUCT SEGMENTS
TABLE 61.    CSL: PRODUCT PORTFOLIO
TABLE 62.    GRIFOLS: COMPANY SNAPSHOT
TABLE 63.    GRIFOLS: OPERATING SEGMENTS
TABLE 64.    GRIFOLS: PRODUCT PORTFOLIO
TABLE 65.    KEDRION: COMPANY SNAPSHOT
TABLE 66.    KEDRION: PRODUCT PORTFOLIO
TABLE 67.    LFB: COMPANY SNAPSHOT
TABLE 68.    LFB: PRODUCT SEGMENTS
TABLE 69.    LFB: PRODUCT PORTFOLIO
TABLE 70.    OCTAPHARMA: COMPANY SNAPSHOT
TABLE 71.    OCTAPHARMA: PRODUCT SEGMENTS
TABLE 72.    OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 73.    TAKEDA: COMPANY SNAPSHOT
TABLE 74.    TAKEDA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    LOW BARGAINING POWER OF SUPPLIERS
FIGURE 04.    LOW BARGAINING POWER OF BUYERS
FIGURE 05.    LOW THREAT OF SUBSTITUTION
FIGURE 06.    LOW THREAT OF NEW ENTRANTS
FIGURE 07.    MODERTAE COMPETITIVE RIVALRY
FIGURE 08.    VALUE CHAIN ANALYSIS
FIGURE 09.    MARKET SHARE ANALYSIS, 2017
FIGURE 10.    GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 11.    U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 12.    CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS),  2017-2025
FIGURE 13.    MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 14.    GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS),  2017-2025
FIGURE 15.    FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 16.    UK INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 17.    ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 18.    AUSTRIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS),  2017-2025
FIGURE 19.    RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
REST OF EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 20.    AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS),  2017-2025
FIGURE 21.    CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 22.    INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 23.    JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 24.    REST OF ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 25.    BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 26.    SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 27.    ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS),  2017-2025
FIGURE 28.    TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 29.    REST OF LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 30.    BAXTER: NET SALES, 2015–2017 ($MILLION)
FIGURE 31.    BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32.    BAYER: NET SALES, 2015–2017 ($MILLION)
FIGURE 33.    BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34.    BAYER: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 35.    BIOTEST: NET SALES, 2015–2017 ($MILLION)
FIGURE 36.    BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 37.    BIOTEST: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 38.    CHINA BIOLOGIC NET SALES, 2015–2017 ($MILLION)
FIGURE 39.    CSL: NET SALES, 2015–2017 ($MILLION)
FIGURE 40.    CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41.    CSL: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 42.    GRIFOLS: NET SALES, 2015–2017 ($MILLION)
FIGURE 43.    GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44.    GRIFOLS: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 45.    KEDRION: NET SALES, 2015–2017 ($MILLION)
FIGURE 46.    KEDRION: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 47.    LFB: NET SALES, 2014–2016 ($MILLION)
FIGURE 48.    LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 49.    LFB: REVENUE SHARE BY REGION, 2016 (%)
FIGURE 50.    OCTAPHARMA: NET SALES, 2015–2017 ($MILLION)
FIGURE 51.    TAKEDA: NET SALES, 2015–2017 ($MILLION)
FIGURE 52.    TAKEDA: REVENUE SHARE BY REGION, 2017 (%)